Humacyte Debt to Equity

The latest debt-to-equity ratio for HUMA is 2.12. That is above the Healthcare sector average of -8.5. Investors often review this figure alongside Humacyte's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, HUMA currently prints 2.12 for debt-to-equity ratio, while the sector average sits near -8.5. That is roughly 124.9% above the sector mean. Large gaps often invite a closer look at Humacyte's growth, margins, and balance sheet.

A debt-to-equity ratio of 2.12 for Humacyte is not 'good' or 'bad' on its own. Compare it with the peer average (-8.5) and with HUMA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting HUMA's debt-to-equity ratio (2.12), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Humacyte's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.